Company news

ENDRA Life Sciences Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

August 17, 2026

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

June 25, 2026

ENDRA Life Sciences (NASDAQ: NDRA) Beats Q1 Expectations, TAEUS® Liver Imaging Advances and Strategic Review Acceleration Fuels Investor Awareness

May 27, 2026

ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS(R) Liver Device Demonstrating MRI-like Accuracy and Reproducibility

May 15, 2026

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

May 13, 2026

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 30, 2026

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

March 24, 2026

ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

February 25, 2026

ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active

December 9, 2025

ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

December 4, 2025

ENDRA Life Sciences (NASDAQ: NDRA) Advances Treasury Flywheel and TAEUS® Liver Imaging Platform

December 2, 2025

ENDRA Life Sciences (NASDAQ: NDRA) Advances "Yield-to-Innovation" Strategy to Accelerate Breakthrough Liver Imaging Technology

November 25, 2025

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

November 20, 2025

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

November 17, 2025

ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA

November 12, 2025

ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings

October 22, 2025

ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

October 12, 2025

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

August 14, 2025

ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

June 16, 2025

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

May 15, 2025

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

March 31, 2025

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

March 31, 2025

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

November 21, 2024

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

November 14, 2024

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

November 5, 2024

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

October 21, 2024

ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements

August 27, 2024

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

August 21, 2024

ENDRA Life Sciences Announces Reverse Stock Split

August 15, 2024

ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

August 12, 2024

ENDRA Life Sciences Announces Leadership Changes

August 12, 2024

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

June 3, 2024

ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update

May 13, 2024

ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024

May 6, 2024

ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International Patents

May 1, 2024

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 27, 2024

ENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024

March 20, 2024

ENDRA Life Sciences Installs First TAEUS System in the UK

February 26, 2024

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with New Patents in U.S., China and Europe

February 13, 2024

ENDRA Life Sciences Secures 39th U.S. Patent for TAEUS® System Technology

November 28, 2023

ENDRA Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 13, 2023

ENDRA Life Sciences Achieves Intellectual Property Milestone with Issuance of Three New Patents

November 7, 2023

ENDRA Life Sciences to Report Third Quarter 2023 Financial Results on November 14, 2023

November 6, 2023

ENDRA Life Sciences' TAEUS De Novo Submission Advances to Next Stage of Review with FDA

August 29, 2023

ENDRA Life Sciences Expands Intellectual Property with Issuance of U.S. and European Patents

August 22, 2023

ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA

August 13, 2023

ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update

August 13, 2023

ENDRA Life Sciences to Report Second Quarter 2023 Financial Results on August 14, 2023

July 31, 2023

ENDRA Life Sciences Reports First Quarter 2023 Financial Results and Provides a Business Update

May 14, 2023

Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 12 decks. Every deck is listed under its year.